Open-Angle Glaucoma Clinical Research Expands With 20+ Emerging Therapies, Reports DelveInsight | FDA Approvals, Treatments, Drug Developers

Several companies are actively advancing innovation in the Open-Angle Glaucoma market, including Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS, among others.

According to DelveInsight's analysis, the worldwide Open-Angle Glaucoma development pipeline includes over 18 organizations collectively progressing more than 20 investigational treatment candidates. The evaluation encompasses clinical trial developments, therapeutic approaches, mechanisms of action, delivery methods, and key advancement milestones.

The "Open Angle Glaucoma Pipeline Insight" report offers a comprehensive evaluation of the current clinical trial landscape, along with forward-looking insights into growth opportunities within the Open-Angle Glaucoma market.
This pipeline report delivers an extensive clinical and commercial review of drug candidates spanning preclinical research through marketed therapies. It also features detailed product profiles highlighting mechanisms of action, clinical trial results, regulatory developments, and ongoing activities such as technological advancements, strategic partnerships, mergers and acquisitions, funding events, and special regulatory recognitions.

Request a Sample Report here @ Open Angle Glaucoma Pipeline Outlook - https://www.delveinsight.com/report-store/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Open Angle Glaucoma Pipeline Report
• Companies across the globe continue to make consistent progress in developing novel treatment solutions for Open-Angle Glaucoma, with meaningful advancements achieved in recent years.
• Leading organizations such as Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS, and others remain actively involved in advancing therapies for Open-Angle Glaucoma care.
• Promising pipeline candidates, including TO-O-1001, BTQ-1902, NCX 470, and several additional therapies, are expected to play a critical role in shaping the future treatment paradigm for Open-Angle Glaucoma.
• In April 2025, Perfuse Therapeutics, Inc. announced findings from a Phase 1/2a clinical trial evaluating the safety, tolerability, and pharmacodynamic profile of a single dose of the PER-001 intravitreal implant in Open-Angle Glaucoma patients.
• In March 2025, Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX) confirmed that the final patient completed the last study visit in its Whistler Phase 3b trial, which assessed NCX 470's dual nitric oxide-prostaglandin analog mechanism for intraocular pressure reduction. NCX 470 remains Nicox's lead pipeline asset and continues in Phase 3 development for Open-Angle Glaucoma and ocular hypertension.
• In February 2025, Qlaris Bio, Inc. disclosed positive topline results from two U.S. Phase II studies-Osprey and Apteryx-investigating QLS-111 in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT), successfully meeting all primary and secondary endpoints.
• In January 2025, Glaukos Corporation (NYSE: GKOS) launched a Phase 2b/3 clinical development program for iDose TREX, an advanced sustained-release drug delivery system designed to provide nearly double the drug capacity of the original iDose TR.
• In October 2024, Phase II data for Neurotech Pharmaceuticals' NT-501 encapsulated cell therapy were presented at the American Academy of Ophthalmology (AAO) 2024 Annual Meeting in Chicago. The CNTF-releasing implant demonstrated a favorable safety and tolerability profile in patients with primary open-angle glaucoma, with no serious adverse events reported.
• In March 2024, MediPrint® Ophthalmics announced the successful completion of its Phase 2b glaucoma clinical trial, reporting encouraging study outcomes.
• In February 2024, Skye Bioscience completed patient enrollment for its Phase 2a clinical trial evaluating SBI-100 ophthalmic emulsion for glaucoma and ocular hypertension.
• At ASCRS 2024, Phase II clinical data were presented for a travoprost intracameral implant in patients diagnosed with Open-Angle Glaucoma or ocular hypertension.

Open Angle Glaucoma Overview
Open-angle glaucoma is the most common form of glaucoma and is characterized by progressive optic nerve damage resulting from inadequate drainage of aqueous humor through the trabecular meshwork. The condition typically advances slowly and remains asymptomatic in early stages, often leading to delayed diagnosis until significant vision impairment occurs. Key risk factors include increasing age, genetic susceptibility, elevated intraocular pressure, and associated conditions such as diabetes and hypertension. Diagnosis commonly involves optic nerve evaluation, visual field testing, and intraocular pressure measurement. Treatment focuses on lowering intraocular pressure through pharmacologic therapies, laser procedures, or surgical interventions to preserve vision and slow disease progression.

Download a Free Sample PDF to explore the Open Angle Glaucoma Pipeline Therapeutic Assessment - Open Angle Glaucoma Treatment Market - https://www.delveinsight.com/sample-request/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Open Angle Glaucoma Routes of Administration
The report categorizes pipeline therapies based on their delivery methods, including:
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Open Angle Glaucoma Molecule Classification
Pipeline candidates are grouped according to molecular type, such as:
• Monoclonal antibodies
• Small-molecule drugs
• Peptide-based therapies

Open Angle Glaucoma Pipeline Therapeutics Evaluation
• Assessment by product category
• Analysis by development phase and product type
• Evaluation based on route of administration
• Stage-wise analysis by delivery method
• Classification by molecular type
• Stage-wise breakdown by molecular class

DelveInsight's Open Angle Glaucoma pipeline analysis monitors more than 20 therapeutic programs across multiple stages of development, including:
• Late-stage programs (Phase III)
• Mid-stage programs (Phase II)
• Early-stage programs (Phase I)
• Preclinical and discovery initiatives
• Discontinued and inactive pipeline assets
• Route-of-administration profiling
The report also includes additional product-specific insights. Download the Open Angle Glaucoma pipeline analysis to gain a comprehensive understanding of emerging drugs and therapeutic innovations influencing the market.

Open Angle Glaucoma Pipeline Intelligence
The report offers in-depth competitive and strategic insights, including:
• Detailed company profiles highlighting Open-Angle Glaucoma development activities and pipeline depth
• Classification of pipeline assets into early-, mid-, and late-stage development
• Identification of companies involved in both active and discontinued programs
• Segmentation of therapies by development phase, route of administration, therapeutic target, monotherapy or combination use, mechanism of action, and molecular type
• Comprehensive analysis of strategic initiatives, including partnerships, academic collaborations, licensing agreements, and funding activities shaping future market growth

Download a Sample PDF to explore Open Angle Glaucoma drugs, therapies, clinical trials, and FDA approvals - - https://www.delveinsight.com/sample-request/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Open Angle Glaucoma Pipeline Drug Insight
• Geographic Coverage: Global
• Key Companies: Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS, and others
• Key Therapies: TO-O-1001, BTQ-1902, NCX 470, and additional pipeline candidates
• Therapeutic Scope: Approved treatments and emerging investigational therapies
• Market Dynamics: Key drivers, restraints, and challenges influencing the Open-Angle Glaucoma market

Request a Sample PDF Report for the Open Angle Glaucoma Pipeline and Clinical Trial Assessment - Open Angle Glaucoma Therapeutics Market - - https://www.delveinsight.com/sample-request/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.